Epitopea

Epitopea is a private, pre-clinical stage biotech founded in 2020, with dual headquarters in Cambridge, UK, and Montreal, Canada. The company's core innovation is the CryptoMap™ platform, which computationally and experimentally mines the 'dark immunopeptidome' to discover shared tumor antigens derived from aberrant gene expression, enabling the development of off-the-shelf RNA immunotherapies. With a focus on solid tumors like melanoma and NSCLC, Epitopea is building its pipeline and team, recently expanding its Scientific Advisory Board and clinical development capabilities as it accelerates toward the clinic. The company operates as a platform-based therapeutics developer and is currently pre-revenue.

CryptoMap™ platform identifies shared, aberrantly expressed tumor-specific antigens (Cryptigen™ TSAs) hidden in non-coding 'junk DNA' for the development of off-the-shelf RNA immunotherapies.

Epitopea competes in the crowded cancer vaccine/immunotherapy arena, facing rivals targeting personalized neoantigens (e.g., BioNTech, Moderna Oncology) and other shared tumor-associated antigens like cancer-testis antigens. Its differentiation lies in its focus on the novel aeTSA class derived from epigenetically activated 'junk DNA,' a less-explored source of targets.